Author of

• 17398

  +

  P2.01 - Poster Session with Presenters Present (ID 461)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17418

    +

    P2.01-020 - Identification of a Three-lncRNA Signature for Lung Cancer Diagnosis and Prognosis (ID 5609)

    14:30 - 14:30  |  Author(s): C. Wang
    • Abstract

    Background:
    Lung cancer is one of the leading causes of cancer-related death in the world. Metastasis is the main cause of death. There is still lack of ideal predictive and prognostic biomarkers. Human lncRNA plays important structural and functional roles in many biology progresses. Increasing studies have demonstrated that the abnormal expression of lncRNA is correlated to cancer progress in variant types of cancer, and lncRNA is considered as a potential valuable biomarker for diagnosis, treatment and prognosis of cancer.
    
    Methods:
    Here, we investigated the lncRNA expression profile in lung adenocarcinoma with lymph node metastasis and without lymph node metastasis (n=5 vs 5) by microarray assay. Three lncRNAs were selected for further verification by qRT-PCR in a training cohort including 118 paired lung cancer and the adjacent normal tissues and a test cohort including 60 paired tissues. In addition，we analyzed the correlation of the lncRNAs with clinicopathological features and survival.
    
    Results:
    We observed 245 significantly differentially expressed lncRNAs between lung adenocarcinoma with lymph node metastasis and without lymph node metastasis. Gene ontology analysis showed that the lncRNAs may be involved in several important biological progresses. ROC curves revealed that a 3-lncRNA signature distinguished not only lung cancer with lymph node metastasis from lung cancer without lymph node metastasis but also lung cancer from normal tissue. Moreover, the 3-lncRNA signature showed prognostic value by survival analysis. Multivariable Cox regression analysis showed that the signature was an independent prognostic factor for lung cancer patients. In another independent test cohort including 60 paired lung cancer and normal tissues, we validated the diagnostic and prognostic values of the 3-lncRNA signature.
    
    Conclusion:
    Our results identified a new 3-lncRNA signature for the diagnosis and prognosis of lung cancer, suggesting the potential clinical utility of lncRNA biomarkers in lung cancer.